Enanta Pharmaceuticals Announces New Data Presentations on EDP-305, an FXR Agonist for NASH and PBC, at The Liver Meeting® 2017

September 27, 2017
Download this Press Release

WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 27, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new data presentations on EDP-305, Enanta's lead FXR agonist being developed for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC), have been accepted for presentation at The Liver Meeting® 2017, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place October 20-24, 2017 in Washington, D.C.

Additionally, Enanta has submitted an abstract to AASLD for consideration of Late Breaking data from its Phase 1 clinical study of EDP-305, including pharmacokinetic and biomarker data, and is planning to have this data announced either in a Late Breaking presentation or poster at The Liver Meeting or as otherwise presented by Enanta.

According to AASLD, the following abstract titles can now be viewed at the AASLD website at https://www.aasld.org/events-professional-development/liver-meeting/program-0/preliminary-program, and the full abstracts will be available in print and posted online on October 1, 2017.

Friday, October 20
Poster Presentation, 8:00 am - 5:30 pm ET
Session: Basic Fibrosis Research and Stellate Cell Biology
#367 – "A novel FXR agonist EDP-305 potently suppresses hepatic stellate cell activation and hepatic fibrosis in chronic mouse models of biliary and metabolic liver disease"

Monday, October 23
Oral Presentation, 8:00 - 9:30 am ET
Parallel Session 23: Steatosis and Steatohepatitis: Experimental I
#162 – "Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis"

Monday, October 23
Poster Presentation, 8:00 am - 5:30 pm ET
Session: Steatohepatitis: Experimental
#1988 – "EDP-305 favorably regulates lipoprotein mechanism *in vitro*"

About Enanta
Enanta Pharmaceuticals has used its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, paritaprevir and glecaprevir, discovered and developed through Enanta's collaboration with AbbVie, have now been approved in jurisdictions around the world as part of AbbVie's direct-acting antiviral (DAA) regimens for the treatment of hepatitis C virus (HCV) infection, including the U.S. marketed regimens MAVYRET™ (glecaprevir/pibrentasvir) and VIEKIRA PAK® (paritaprevir/ritonavir/ombitasvir/dasabuvir).

Royalties and milestone payments from the AbbVie collaboration are helping to fund Enanta's research and development efforts, which are currently focused on the following disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). Please visit www.enanta.com for more information.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170927006300/en/

Source: Enanta Pharmaceuticals, Inc.

Investor Contact
Enanta Pharmaceuticals, Inc.
Carol Miceli, 617-607-0710
cmiceli@enanta.com
or
Media Contact
MacDougall Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com